Overview

Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma

Status:
Recruiting
Trial end date:
2035-11-01
Target enrollment:
Participant gender:
Summary
Master protocol for cell therapy, Phase 1 proof-of-concept studies., in relapsed and refractory multiple myeloma and includes long-term safety follow-up.
Phase:
Phase 1
Details
Lead Sponsor:
Arcellx, Inc.